Qiming Medical-B (02500) plans to issue new shares and convertible bonds to Hangzhou Yingzhiqin No. 3 Equity Investment Partnership to raise no more than 500 million yuan

Zhitong Finance App News, Qiming Medical-B (02500) announced that on September 10, 2026, the company plans to issue approximately 184.5 million shares to be subscribed to Hangzhou Yingzhiqin No. 3 Equity Investment Partnership (limited partnership) (the cost is about HK$199 million if the shares to be subscribed are H shares, or about RMB 172 million if the shares to be subscribed are domestic shares) and convertible bonds (the principal amount does not exceed HK$380 million). The subscription price is HK$1.078 per share, a 7.9% discount on the closing price of H shares of HK$1.170 per share as reported by the Stock Exchange on the date of the subscription agreement. The initial convertible bonds were HK$1.1858 per share, a 1.4% premium per share over the closing price of H shares reported by the Stock Exchange on the date of the subscription agreement of HK$1.170.

The total subscription proceeds and net proceeds (after deducting related expenses and professional expenses) are estimated to be approximately $500 million and $476.5 million respectively. The net proceeds are intended to cover R&D, clinical and regulatory expenses, supplement general corporate working capital requirements, and repay outstanding loans.